How to Accelerate and Enhance ADC Therapies
Abstract of the Webinar: The ADCore product line offers versatile intermediates that simplify the synthesis of common ADC payloads (dolastatins, maytansinoids, and PBDs) by greatly reducing the number of synthetic steps. This translates to savings in development and manufacturing costs and shorter timelines to the clinic. To address the poor solubility of many ADC payloads, ChetoSensar™ was developed to significantly increase the hydrophilicity of the drug linker, which has been shown to also substantially increase the efficacy of ADCs and broaden the therapeutic window. Lastly, the ADC Express™ service leverages conjugation chemistry and analytical expertise to help design and quickly synthesize sets of potential ADC therapies suitable for screening to simplify candidate selection and get ADC therapies to market faster.
In this webinar, you will learn about:
- The advantages of using advanced intermediates to develop ADC therapies
- How to increase ADC solubility and efficiency
- Fast, small-scale ADC library generation
- Seamless supply chain with reduced complexity and regulatory support
Link to register for the Webinar: https://event.on24.com/wcc/r/3690258/09841EDFFBB09CE3EAF54ED50D4F9DA9?partnerref=ebblog
He studied synthetic organometallic chemistry and received his Ph.D. from the University of Iowa.
Jeff has a bachelor’s degree in Chemistry from the University of Illinois-Champaign, Champaign, IL and a master’s degree in Organic Synthesis from Rice University, Houston, TX with his thesis on perfluoro-cholesterol analogs as treatment for Familial Hypercholesterolemia.
